Hippocampal remodelling after MDMA neurotoxicity: A single case study

World Journal of Biological Psychiatry

Volumn 10, Issue 4 PART 3, 2009, Pages 961-968

  Nifosì, Francesco ^a   Martinuzzi, Andrea ^b   Toffanin, Tommaso ^a   Costanzo, Raffaella ^a   Vestri, Alec ^b   Battaglia, Mariamalia ^b   Bertagnoni, Gian E ^c   Lupi, Andrea ^c   Amistà, Pietro ^a   Carollo, Carla ^a   Perini, Giulia ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b SCIENTIFIC INSTITUTE   (Italy)

^c Vicenza Hospital   (Italy)

Author keywords

Hippocampus; MDMA; MRI; Neurogenesis

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; FLUORODEOXYGLUCOSE F 18; OLANZAPINE; RIVASTIGMINE; TIAGABINE; VALPROIC ACID; ANTICONVULSIVE AGENT; PSYCHEDELIC AGENT;

ADOLESCENT; ARTICLE; CASE REPORT; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; FEMALE; HIPPOCAMPUS; HUMAN; LABORATORY TEST; MOOD DISORDER; NERVE ENDING; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SEIZURE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; METABOLISM; OCCIPITAL LOBE; PARIETAL LOBE; THERMOREGULATION; TOXICITY AND INTOXICATION;

ADOLESCENT; ANTICONVULSANTS; BODY TEMPERATURE REGULATION; COGNITION DISORDERS; ELECTROENCEPHALOGRAPHY; FEMALE; HALLUCINOGENS; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; NEUROTOXICITY SYNDROMES; OCCIPITAL LOBE; PARIETAL LOBE; POSITRON-EMISSION TOMOGRAPHY; SEIZURES; VALPROIC ACID;

EID: 77949497403     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970701870933     Document Type: Article

References (25)

1. Affolter F. 1981. Perceptual processes as prerequisites for complex human behaviour. Int Rehabil Med 3:3-10.
2. Budisavljevic MN, Stewart L, Sahn SA, Ploth DW. 2003. Hyponatremia associated with 3,4-methylenedioxymethylam-phetamine ('Ecstasy') abuse. Am J Med Sci 326:89-93.
3. Eichenbaum H, Otto T, Cohen NJ. 1992. The hippocampus-what does it do? Behav Neural Biol 57:2-36.
4. Daniels-Zide E, Ben-Yishay Y. 2000. Holistic day program. In: Chirstensen and Uzzel, editors. International handbook of neuropsychological rehabilitation. Dordrecht/Boston: Kluwer Academic/Plenum Publishers.
5. Duffau H. 2006. Brain plasticity: from pathophysiological mechanisms to therapeutic applications. J Clin Neurosci 13:885-897.
6. Fallon JK, Shah D, Kicman AT, et al. 2002. Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release. Ann NY Acad Sci 965:399-409
7. Gould E, Beylin A, Tanapat P, Reeves A, Shors TJ. 1999. Learning enhances adult neurogenesis in the hippocampal formation. Nat Neurosci 2:260-265. (Pubitemid 30491297)
8. Gouzoulis-Mayfrank E, Timm B, Rezk M, Hensen G, Daumann J. 2003. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog Neuropsychopharmacol Biol Psychiatry 27:819-827.
9. Guo Q, Fu W, Sopher BL, et al. 1999. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med 5:101-107.
10. Jacobsen LK, Mencl WE, Pugh KR, Skudlarski P, Krystal JH. 2004. Preliminary evidence of hippocampal dysfunction in adolescent MDMA ('ecstasy') users: possible relationship to neurotoxic effects. Psychopharmachology (Berlin) 173:383-390.
11. Lupi A, Bertagnoni G, Salgarello M, Orsolon P, Malfatti V, Zanco P. 2007. Cerebellar vermis relative hypermetabolism: an almost constant PET finding in injured brain. Clin Nucl Med 32: 445-451
12. Marchesi C, Tonna M, Maggini C. 2007. Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse. World J Biol Psychiatry 10:1-.
13. McEwen BS. 2000. Effects of Adverse Experiences for Brain Structure and Function. Biol Psychiatry 48:721-731.
14. McEwen BS, Magarinos AM. 2001. Stress and hippocampal plasticity: implications for the pathophysiology of affective disorders. Hum Psychopharm 16:7-19.
15. Pantel J, O'Leary DS, Cretsinger K, et al. 2000. A new method for the in vivo volumetric measurement of the human-hippocampus with high neuroanatomical accuracy. Hippocampus 10: 752-758.
16. Peng W, Simantov R. 2003. Altered gene expression in frontal cortex and midbrain of 3,4-methylenedioxymethamphetamine (MDMA) treated mice: differential regulation of GABA transporter subtypes. J Neurosci Res 72:250-258.
17. Perini G, Nifos̀ F, Toffanin T, Gatto C, Ghelli G, Amista P. 2004. Recurrent major depression and nuclear magnetic resonance: a volumetric study. In: Proceedings of the 7th Congress of European Society for Clinical Neuropharmacology. J Neural Transm 111(5): I-XLVII abstract.
18. Pruessner JC, Li LM, Serles W, et al. 2000. Volumetry of hippocampus and amygdala with high-resolution mri and three-dimensional analysis software: minimizing the discrepancies between laboratories. Cereb Cortex 10:433-442.
19. Quinton MS, Yamamoto BK. 2006. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J 8:337-347.
20. Ricaurte GA, Yuan J, McCann UD. 2000. 3,4-methylenediox-ymethamphetamine (Ecstasy)-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42:5-10.
21. Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R. 1998. MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend 52: 85-90.
22. Sheline YI, Gado MH, Kraemer HC. 2003. Untreated depression and hippocampal volume loss. Am J Psychiatry 160:1516-1518.
23. Voss HU, Uluc AM, Dyke JP, et al. 2006. Possible axonal regrowth in late recovery from the minimally conscious state. J Clin Invest 116:2005-2011.
24. Warner-Schmidt JL, Duman RS. 2006. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 16:239-249.
25. Yucel M, Lubman DI. 2007. Neurocognitive and Neuroimaging evidence of behavioural dysregulation in human drug addiction: implications for diagnosis, treatment and prevention. Drug Alcohol Rev 26:33-39.